| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/18/2004 | US20040054004 Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, in flammation, hypersensitivity or pain |
| 03/18/2004 | US20040053993 Compositions of tocol-soluble therapeutics |
| 03/18/2004 | US20040053987 Bis-heterocyclic compounds with antitumour and chemosensitising activity |
| 03/18/2004 | US20040053982 Such as 3-(2-(6-methyl-pyridin-2-ylamino)-5-(1,2,4)triazol-1-yl-thiazol-4 -yl)benzonitrile for treatment of inflammatory or obstrucive airways diseases |
| 03/18/2004 | US20040053975 Combinations of HMG-CoA reductase inhibitors and nicotinic acid compounds and methods for treating hypelipidemia once a day at night |
| 03/18/2004 | US20040053974 Medicinal compositions containing diuretic and insulin resistance-improving agent |
| 03/18/2004 | US20040053955 An immunosuppressants for treating allograft rejection, transplant rejection, psoriasis, and rheumatoid arthritis, a 9,10-dihydro-9-oxo-acridine-3-yl- derivatives |
| 03/18/2004 | US20040053953 Treatment of chemokine mediated diseases |
| 03/18/2004 | US20040053949 Protein kinase c inhibitors; antiinflammatory agents; immunosuppresants; antidiabetic agents; immunomodulators |
| 03/18/2004 | US20040053947 Pyrrolo[2,3-D]pyrimidine compounds |
| 03/18/2004 | US20040053946 Cancer treatment method |
| 03/18/2004 | US20040053938 Administering sildenafil citrate; inhalation therapy |
| 03/18/2004 | US20040053935 Anticancer agents |
| 03/18/2004 | US20040053934 Anticancer agents |
| 03/18/2004 | US20040053919 Administering a patient suffering from arthritic diseases, a 1,4-benzodiazapine or a 1,4-benzothiazepine derivative for treating such degenerative joint diseases |
| 03/18/2004 | US20040053915 Pyrazolopyridine derivatives |
| 03/18/2004 | US20040053903 Method to treat cardiofibrosis with a combination therapy of an angiotensin II antagonist and an epoxy-steroidal aldosterone antagonist |
| 03/18/2004 | US20040053902 Novel composition and method for treatment of upper respiratory conditions |
| 03/18/2004 | US20040053900 Administering to a mammal a combination of cyclooxygenase-2 inhibitor and aromatase inhibitor for the prevention, or inhibition of a neoplasia, a neoplasia-related disorder, or osteoporosis in mammal in need |
| 03/18/2004 | US20040053898 For organ specific therapy; for treatment of menopausal symptoms, hormone-deficiency diseases and neurodegenerative diseases |
| 03/18/2004 | US20040053897 Selective androgen receptor modulators (SARMs); for inhibition of mitogenic action of testosterone and dihydrotestosterone; also for treatment of hair loss |
| 03/18/2004 | US20040053890 Naphthalene derivatives |
| 03/18/2004 | US20040053885 Use of hyaluronic acid derivatives for the prevention of inflammatory arthritis |
| 03/18/2004 | US20040053882 Comprises sterically hindered platinum coordination compound such as (SP-4-3)-(cis-aminedichloro-(2-methylpyridine)platinum complex, non- platinum based anticancer agent (taxol), and carrier; kits |
| 03/18/2004 | US20040053880 Nucleic acid compositions for stimulating immune responses |
| 03/18/2004 | US20040053863 Sensitization of HER-2/neu overexpressing cancer cells to chemotherapy |
| 03/18/2004 | US20040053860 Flavonoid derivatives for the treatment of eczema |
| 03/18/2004 | US20040053858 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract |
| 03/18/2004 | US20040053852 Preventing desensitization of receptors |
| 03/18/2004 | US20040053851 Association of calpain inhibitors and reactive oxygen species trapping agents |
| 03/18/2004 | US20040053842 Cholesterol ester transfer protein inhibitors for use in treating atherosclerosis optionally in combination with other antihypertensive agents |
| 03/18/2004 | US20040053833 Relates to regulation of activity of NET (ERP/SAP-2) protein and to compounds which modify or regulate NET protein activity; methods of screening for agonists or antagonists of NET in order to identify new pro- or anti-angiogenic compounds |
| 03/18/2004 | US20040053832 Prevention of Ca2+-influx and reduction of cAMP/cGMP-ratio in immune effector cells by use of combination of Ca-antagonist, and an agent able to decrease the intracellular cAMP/cGMP-ratio |
| 03/18/2004 | US20040053817 Proinsulin C-peptide is present in an absorbable matrix of polyglycolide-lactide copolymers; antidiabetic agents |
| 03/18/2004 | US20040053813 Method of extending the dose range of vitamin D compounds |
| 03/18/2004 | US20040053812 Methods |
| 03/18/2004 | US20040053379 Method of producing polyunsaturated fatty acids, novel biosynthesis genes, and novel plant expression constructs |
| 03/18/2004 | US20040053357 Nucleic acid encoding kv10.1 a voltage-gated potassium channel from human brain |
| 03/18/2004 | US20040053299 Regulated activation of cell-membrane receptors by metal-chelating agonists |
| 03/18/2004 | US20040053281 Comprises enzymatic polypeptide associated with fatty acid metabolism for diagnosing, treating and preventing cancer, neurodegenerative, autoimmune/inflammatory, gastrointestinal and cardiovascular disorders |
| 03/18/2004 | US20040053278 Smad6 and uses thereof |
| 03/18/2004 | US20040053265 Using differential gene expression of flotillin gene products to diagnose and prognose brain disorders |
| 03/18/2004 | US20040053262 Supressor gene |
| 03/18/2004 | US20040053220 Replication assay for detecting anti-viral substances |
| 03/18/2004 | US20040052922 Nutritional and therapeutical preparations having antioxidant activity |
| 03/18/2004 | US20040052874 Synergistic composition for treating leukemia |
| 03/18/2004 | US20040052873 Bioavailability / bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof |
| 03/18/2004 | US20040052871 Health enhancement system |
| 03/18/2004 | US20040052870 Cyclooxygenase (COX-2) inhibitors; for treatment/prevention of inflammation; nutraceuticals; for treatment of nervous system disorders |
| 03/18/2004 | US20040052866 Administering gaseous carbon monoxide; also for treatment of alcoholism |
| 03/18/2004 | US20040052864 Comprises decitabine as methylation inhibitor; kits; tumor suppressor genes/proteins; interleukins; vaccines |
| 03/18/2004 | US20040052843 Controlled release dosage forms |
| 03/18/2004 | US20040052842 Delayed and immediate release dosage forms; once a day administration; maximum serum concentration is reached in </=12 hours |
| 03/18/2004 | US20040052841 Pharmaceutical preparation with retarding active ingredient release, method for its production and its use |
| 03/18/2004 | US20040052837 Lipid conjugated anti-cancer drugs and methods of use thereof |
| 03/18/2004 | US20040052787 Screening for menstruation disorders; measurement nucleic acids or protein |
| 03/18/2004 | US20040052786 Erbb4 antagonists |
| 03/18/2004 | US20040052785 Synergistic mixtures; antitumor agents |
| 03/18/2004 | US20040052778 Mixture of iodide, thiocyanates, periodic acid and peroxygenase; viricides; killing spores |
| 03/18/2004 | US20040052754 Complexes of phosphate derivatives |
| 03/18/2004 | US20040052741 Compositions for the treatment of pigmentation disorders and methods for their manufacture |
| 03/18/2004 | US20040052739 Sunscreen agents; radiation resistance |
| 03/18/2004 | US20040052732 Synergistic mixture of antiserotonine agents and glucocorticoids; inhalation |
| 03/18/2004 | DE10241395A1 Coffein enthaltende Zusammensetzung als Hautpflegemittel Caffeine-containing composition as a skin care product |
| 03/18/2004 | DE10238677A1 Mixture for oral ingestion, useful as a medicament, dietetic product or dietary supplement, comprises defined amounts of vitamins, selenium and zinc |
| 03/18/2004 | CA2536010A1 Boronic acid salts useful in parenteral formulations for selective thrombin inhibition |
| 03/18/2004 | CA2535792A1 Boronic acid salts ant their use in the treatment of thrombosis |
| 03/18/2004 | CA2535788A1 Multivalent metal salts of boronic acids for treating thrombosis |
| 03/18/2004 | CA2501924A1 Non-nucleoside reverse transcriptase inhibitors |
| 03/18/2004 | CA2497975A1 Combined immediate release and extended release analgesic composition |
| 03/18/2004 | CA2497902A1 Smg-1 binding protein and screening method for substances that can regulate the activity thereof |
| 03/18/2004 | CA2497873A1 Novel diagnostic and therapeutic methods and reagents therefor |
| 03/18/2004 | CA2497832A1 Pharmaceuticals formulations and methods for modified release of statin drugs |
| 03/18/2004 | CA2497828A1 A method of extending the dose range of vitamin d compounds |
| 03/18/2004 | CA2496888A1 Epitope sequences |
| 03/18/2004 | CA2496566A1 Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer |
| 03/18/2004 | CA2495939A1 Cathepsin cysteine protease inhibitors |
| 03/18/2004 | CA2493974A1 Pharmaceutical dosage form comprising a sulfite compound |
| 03/18/2004 | CA2441469A1 Methods and compositions for treating alzheimer's disease |
| 03/17/2004 | EP1398377A1 Growth differentation Factor-7 |
| 03/17/2004 | EP1398038A1 Botulinum toxin pharmaceutical compositions |
| 03/17/2004 | EP1398033A2 Use of benzodiazepines for treating autoimmune diseases, inflammations, neoplasies, viral infections and atherosclerosis |
| 03/17/2004 | EP1398030A2 Dipeptidyl peptidase IV effectors |
| 03/17/2004 | EP1398024A2 Uses for thyroid hormone compounds |
| 03/17/2004 | EP1397957A2 Betulinic acid derivatives and uses therefor |
| 03/17/2004 | EP1397683A2 Methods for identifying compounds for treatment of ibd |
| 03/17/2004 | EP1397681A1 Method for identification of agents for the treatment of diabetes |
| 03/17/2004 | EP1397507A1 Methods and compositions for treating cardiovascular disease using 10218 |
| 03/17/2004 | EP1397503A2 Neuroblastoma cell lines expressing the alpha2delta subunit of calcium channels and methods therefore |
| 03/17/2004 | EP1397494A2 Fungal gene cluster associated with pathogenesis |
| 03/17/2004 | EP1397385A2 Methods for treating disorders of the nervous and reproductive systems |
| 03/17/2004 | EP1397364A1 Novel pyrrole derivatives as pharmaceutical agents |
| 03/17/2004 | EP1397359A1 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors |
| 03/17/2004 | EP1397355A1 Pyridyl cyanoguanidine compounds |
| 03/17/2004 | EP1397160A1 Pharmaceutical composition including ace/nep inhibitors and bioavailability enhancers |
| 03/17/2004 | EP1397158A2 USE OF IgM ANTIBODIES AGAINST dsDNA IN SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHRITIS |
| 03/17/2004 | EP1397157A2 Antibacterial agent |
| 03/17/2004 | EP1397156A2 Oral administration of parathyroid hormone and calcitonin |
| 03/17/2004 | EP1397153A2 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
| 03/17/2004 | EP1397151A2 Wnv core protein/capsid interacting protein and uses of the same |